(Q34520598)

2 August 2017

0 references

Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis (English)

1 reference

Helicobacter pylori infectious disease

2 August 2017

0 references

0 references

1 reference

2

Subbaramiah Sridhar

1 reference

2 August 2017

Jia Qing Huang

1

1 reference

PubMed ID

11809181

2 August 2017

Richard H Hunt

series ordinal

3

1 reference

PubMed ID

11809181

2 August 2017

language of work or name

English

0 references

publication date

1 January 2002

1 reference

2 August 2017

1 reference

2 August 2017

359

1 reference

2 August 2017

14-22

1 reference

2 August 2017

9300

1 reference

How does Helicobacter pylori infection interact with non-steroidal anti-inflammatory drugs?

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Nonsteroidal anti-inflammatory drug gastropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Does eradication of Helicobacter pylori impair healing of nonsteroidal anti-inflammatory drug associated bleeding peptic ulcers? A prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Nonsteroidal anti-inflammatory drug-associated upper gastrointestinal lesions in rheumatoid arthritis patients. Relationships to gastric histology, Helicobacter pylori infection, and other risk factors for peptic ulcer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Severe gastric mucosal damage induced by NSAIDs in healthy subjects is associated with Helicobacter pylori infection and high levels of serum pepsinogens

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Campylobacter-like organisms, nonsteroidal anti-inflammatory drugs and gastric lesions in patients with rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Helicobacter pylori associated chronic gastritis and peptic ulceration in patients taking non-steroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Chemical gastritis and Helicobacter pylori related gastritis in patients receiving non-steroidal anti-inflammatory drugs: comparison and correlation with peptic ulceration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Gastric and duodenal mucosal blood flow in patients receiving non-steroidal anti-inflammatory drugs--influence of age, smoking, ulceration and Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Users' guides to the medical literature. VI. How to use an overview. Evidence-Based Medicine Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Methodologic guidelines for systematic reviews of randomized control trials in health care from the Potsdam Consultation on Meta-Analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Guidelines for application of meta-analysis in environmental epidemiology. ISLI Risk Science Institute

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Peptic ulcer bleeding: interaction between non-steroidal anti-inflammatory drugs, Helicobacter pylori infection, and the ABO blood group system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Interaction between Helicobacter pylori and non-steroidal anti-inflammatory drugs in peptic ulcer bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Guidelines for reading case-control studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Heterogeneity in meta-analysis of data from epidemiologic studies: a commentary

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Invited commentary: benefits of heterogeneity in meta-analysis of data from epidemiologic studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Neutrophils, Helicobacter pylori, and nonsteroidal anti-inflammatory drug ulcers.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Prevalence of Helicobacter pylori infection and its effect on symptoms and non-steroidal anti-inflammatory drug induced gastrointestinal damage in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Helicobacter pylori infection, ABO blood group, and effect of misoprostol on gastroduodenal mucosa in NSAID-treated patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Helicobacter pylori: a risk and severity factor of non-steroidal anti-inflammatory drug induced gastropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Interaction of NSAIDs and Helicobacter pylori on gastrointestinal injury and prostaglandin production: a controlled double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Influence of Helicobacter pylori on gastric mucosal adaptation to naproxen in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

The influence of age, gender, Helicobacter pylori and smoking on gastric mucosal adaptation to non-steroidal anti-inflammatory drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Do non-steroidal anti-inflammatory drugs or smoking predispose to Helicobacter pylori infection?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Relationship between Campylobacter pylori and gastritis in healthy humans after administration of placebo or indomethacin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Ulcer risk factors: interactions between Helicobacter pylori infection, nonsteroidal use, and age.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Cure of peptic gastric ulcer associated with eradication of Helicobacter pylori. Finnish Gastric Ulcer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Mucosal erosions in longterm non-steroidal anti-inflammatory drug users: predisposition to ulceration and relation to Helicobacter pylori.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Duodenal histology, ulceration, and Helicobacter pylori in the presence or absence of non-steroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Interrelationships between Helicobacter pylori infection, nonsteroidal antiinflammatory drugs and gastroduodenal disease. A prospective study in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Helicobacter pylori seroprevalence in patients with rheumatoid arthritis: effect of nonsteroidal anti-inflammatory drugs and gold compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Helicobacter pylori-negative duodenal and pyloric ulcer: role of NSAIDs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Serological evidence of infection with Helicobacter pylori may predict gastrointestinal intolerance to non-steroidal anti-inflammatory drug (NSAID) treatment in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Effect of Helicobacter pylori colonisation on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

High prevalence of Helicobacter pylori infection in duodenal ulcer perforations not caused by non-steroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Helicobacter pylori and non-steroidal anti-inflammatory drugs: uncomfortable partners in peptic ulcer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

The effect of Helicobacter pylori infection on NSAID-related gastroduodenal damage in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Helicobacter pylori infection increases the risk of peptic ulcers in chronic users of non-steroidal anti-inflammatory drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Long-term nonsteroidal antiinflammatory drug use and Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Campylobacter pylori associated gastritis in patients with rheumatoid arthritis taking nonsteroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Helicobacter pylori infection is a protective factor for bleeding gastric ulcers but not for bleeding duodenal ulcers in NSAID users

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Role of Helicobacter pylori infection on upper gastrointestinal bleeding in the elderly: a case-control study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: A case-control study☆, ☆☆

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Peptic ulcer bleeding in the elderly: relative roles of Helicobacter pylori and non-steroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Non-steroidal anti-inflammatory drugs, Helicobacter pylori and bleeding gastric ulcer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Helicobacter pylori and the relation to other risk factors in patients with acute bleeding peptic ulcer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Ulcer site and complications: relation to Helicobacter pylori infection and NSAID use

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Comparison of invasive and noninvasive tests for detecting Helicobacter pylori infection in bleeding peptic ulcers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Helicobacter pylori infection and the risk for duodenal and gastric ulceration.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Non-steroidal anti-inflammatory drugs and peptic ulcers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

The nonsteroidal anti-inflammatory drugs controversy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907273-2

7 January 2021

10.1016/S0140-6736(02)07273-2

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

11809181